---
title: "The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290982899.md"
description: "The stock of Acadia experienced a surge on Friday following an unexpected announcement by European regulators recommending approval of the Rett syndrome drug, Daybu. This surprising development brought Acadia Pharma closer to a breakout, showcasing a positive turn of events for the company."
datetime: "2026-06-26T14:33:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290982899.md)
  - [en](https://longbridge.com/en/news/290982899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290982899.md)
---

# The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout

The stock of Acadia experienced a surge on Friday following an unexpected announcement by European regulators recommending approval of the Rett syndrome drug, Daybu. This surprising development brought Acadia Pharma closer to a breakout, showcasing a positive turn of events for the company.

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)

## Related News & Research

- [How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story](https://longbridge.com/en/news/294004149.md)
- [ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus](https://longbridge.com/en/news/293825186.md)
- [ACADIA issues press release on FDA Fast Track designation for remlifanserin in Alzheimer’s disease psychosis](https://longbridge.com/en/news/293219067.md)
- [Israel "Izzy" Englander increased his position in this pharma stock by 780%. Does he know something Wall Street doesn't?](https://longbridge.com/en/news/293842675.md)
- [Acadia Pharmaceuticals principal accounting officer James Kihara sells 11,421 shares for $297,940.30](https://longbridge.com/en/news/291194117.md)